图像引导调强放射治疗联合重组人血管内皮抑制素泵注治疗局部晚期不能手术的老年非小细胞肺癌患者的疗效  

Efficacy of image-guided radiation therapy combined with recombinant human endostatin pump injection in the treatment of elderly patients with locally advanced inoperable non-small cell lung cancer

作　　者：黄世宝 李瑞锋 蒋才慧 HUANG Shibao;LI Ruifeng;JIANG Caihui(Tumor Radiotherapy Area 3,Quanzhou Guangqian Hospital,Quanzhou,Fujian,362321,China)

机构地区：[1]泉州市光前医院肿瘤放疗三区,福建泉州362321

出　　处：《当代医学》2023年第18期117-119,共3页Contemporary Medicine

摘　　要：目的探究图像引导调强放射治疗(IGRT)联合重组人血管内皮抑制素(Endostar)泵注治疗局部晚期不能手术的老年非小细胞肺癌(NSCLC)患者的疗效。方法选取2016年10月至2019年9月本院放疗科收治的30例老年NSCLC患者作为研究对象。患者均给予IGRT联合Endostar治疗,观察患者近期疗效、总生存时间。结果患者临床有效率为80.00%,疾病控制率为100.00%,患者毒副作用大多数表现为0~2级,主要为血液学毒性、发热、心律失常、心悸等,中位无进展生存时间为10.4(7.86,14.17)个月,中位生存时间为19.5(14.56,23.45)个月。结论IGRT联合Endostar泵注治疗局部晚期不能手术的老年NSCLC患者疗效确切,毒副作用患者可承受,值得临床推广应用。Objective To investigate the efficacy of image-guided radiation therapy(IGRT)combined with recombinant human endostatin(Endostar)pump injection in the treatment of elderly patients with locally advanced inoperable non-small cell lung cancer(NSCLC).Methods A total of 30 elderly patients with NSCLC admitted to the Radiotherapy department of our hospital from October 2016 to September 2019 were selected as the study subjects.All patients were treated with IGRT combined with Endostar,and the short-term efficacy and overall survival time of the patients were observed.Result The clinical effective rate of patients was 80.00%,and the disease control rate was 100.00%.Most of the toxic and side effects of patients were grade 0-2,mainly hematological toxicity,fever,arrhythmia,palpitation,etc.The median progression-free survival time was 10.4(7.86,14.17)months,and the median survival time was 19.5(14.56,23.45)months.Conclusion IGRT combined with Endostar pump injection is effective in the treatment of elderly patients with locally advanced inoperable NSCLC,and the toxic and side effects can be tolerated,which is worthy of clinical promotion and application.

关 键 词：肺肿瘤 老年 重组人血管内皮抑制素 连续静脉泵注 图像引导调强放疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤]